A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico

• Sponsor: Bayer (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04645979
• Collaborator: (none)
• Enrollment: 153
• Location: 1
• Actual Duration (Days): 16
• Patients Per Site Per Month: 291.1

Study Details

Study Description

Brief Summary

Acute allergic rhinitis is a common allergic reaction to things like pollen or dust. It causes inflammation inside the nose, resulting in symptoms similar to the common cold. Allergic rhinitis is also known as hay fever.

In this study, the researchers want to learn what participants think of betamethasone plus loratadine as a treatment for their acute allergic rhinitis. These participants will have used betamethasone plus loratadine as a treatment for their acute allergic rhinitis within the past two months. During the study, participants will complete an online questionnaire about their experience with betamethasone plus loratadine.

Condition or Disease	Intervention/Treatment	Phase
Rhinitis, Allergic	Other: Online survey

Study Design

• Study Type: Observational
• Actual Enrollment: 153 participants
• Observational Model: Other
• Time Perspective: Retrospective
• Official Title: The Perception of Celestamine Treatment in Mexico: a Retrospective Assessment of Consumer Perception of Prior Celestamine Use
• Actual Study Start Date: Nov 11, 2020
• Actual Primary Completion Date: Nov 27, 2020
• Actual Study Completion Date: Nov 27, 2020

Arms and Interventions

Arm	Intervention/Treatment
Participants Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.	Other: Online survey; Participants will be invited to complete an online questionnaire about their experience of product use.

Outcome Measures

Primary Outcome Measures

1. Experience with betamethasone plus loratadine via an online questionnaire [2 months]

   Participants' experiences with betamethasone plus loratadine used under real life conditions.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 50 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participants who used betamethasone plus loratadine within the previous 2 months for the treatment of acute episodes of allergic rhinitis

• Participants allowing to use the data for research and marketing purposes as well as talking to authorities

• Participants allowing us to use the pseudo-randomized individual data for further data analysis

• Able to read and understand the language of the online questionnaire

Exclusion Criteria:

• None

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Many locations	Multiple Locations		Mexico

Sponsors and Collaborators

• Bayer

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Click here to find results for studies related to Bayer products

Publications

None provided.

• Responsible Party: Bayer
• ClinicalTrials.gov Identifier: NCT04645979
• Other Study ID Numbers: 21614
• First Posted: Nov 27, 2020
• Last Update Posted: Nov 29, 2021
• Last Verified: Nov 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Rhinitis; Rhinitis, Allergic

Study Results

No Results Posted as of Nov 29, 2021